Am J Perinatol 2015; 32(02): 193-198
DOI: 10.1055/s-0034-1381319
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Levels of Ischemia-Modified Albumin in Transient Tachypnea of the Newborn

Osman Oztekın
1  Department of Neonatology, Denizli State Hospital, Denizli, Turkey
,
Salih Kalay
2  Department of Neonatology, Kahramanmaras Necip Fazıl Kısakürek State Hospital, Kahramanmaras, Turkey
,
Cuneyt Tayman
1  Department of Neonatology, Denizli State Hospital, Denizli, Turkey
,
Mehmet Namuslu
3  Department of Biochemistry, Faculty of Medicine, Turgut Ozal University, Ankara, Turkey
,
Hüseyin Tugrul Celık
3  Department of Biochemistry, Faculty of Medicine, Turgut Ozal University, Ankara, Turkey
› Author Affiliations
Further Information

Publication History

14 March 2014

22 April 2014

Publication Date:
10 June 2014 (online)

Abstract

Aim The aim of the article is to evaluate ischemia-modified albumin (IMA) levels in infants with transient tachypnea of the newborn (TTN) and to find out its relation to the disease severity.

Patients and Methods Infants with > 37 weeks of gestation, without any respiratory and cardiac symptoms and without any maternal health problems, and diagnosed as TTN were allocated as the study group. Patients with obvious retractions, grunting, hypercarbia (Pco 2 > 60 mm Hg) or hypoxia (oxygen saturation < 88% with Fio 2 of 0.60) were managed with nasal continuous positive airway pressure (CPAP). During the postnatal 0 to 24 hours, blood samples were collected in 2 mL for IMA.

Results A total of 47 patients were diagnosed TTN, and allocated as the study group. Of the 47 patients, 43 patients without respiratory symptoms were enrolled as the control group. IMA levels in TTN were found to be significantly higher (p < 0.05). In addition, IMA levels were significantly increased in the nasal CPAP group versus supplemental oxygen therapy groups (p < 0.05). IMA levels were determined to be significantly higher in the > 3 days of oxygen therapy group (p < 0.05). IMA levels with a cutoff point of 0.87 ABSU, sensitivity of 81.1% and specificity of 69.8% predicted TTN (area under the curve [AUC] = 0.85; p < 0.05). IMA levels with > 0.98 ABSU, 78% sensitivity, and 86% specificity indicated the prediction of CPAP requirement (AUC = 0.86; p < 0.05).

Conclusion IMA levels were significantly higher in infants with diagnosed TTN. Therefore, IMA may be used as a new marker for predicting TTN and disease severity.